Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?

Zhong et al. reported the results of the ADJUVANT/CTONG1104 study (1), a randomized open-label phase III trial enrolling 483 Chinese patients with completely resected (R0) stage II–IIIA (N1-N2) non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)-mutant (defined as exon 19 deletion or exon 21 Leu858Arg) to receive 4 cycles of standard adjuvant Cisplatin and Vinorelbine or 24 months of the EGFR-tyrosine kinase inhibitor (TKI), gefitinib. The primary end-point was disease free survival (DFS).